Skip to content
Screener

Sarepta Therapeutics, Inc. SRPT Business Segments — Other Segment Items

Similar metrics at other companies

KLA Corp. logo
KLACOther Segment Items
$37.83M-14.9%
Pfizer logo
PFEOther Segment Items
-$861M+9.7%
ConocoPhillips logo
COPOther Segment Items
-$3M+50.0%
NRG Energy logo
NRGOther Segment Items
$40M+233%
Sempra Energy logo
SREOther Segment Items
$100M+9.9%
Merck & Co. logo
MRKOther Segment Items
-$138M-494%

Other financials

Income statement

See full
Revenue$401.3M-34.3%
Operating income$13.3M-88.5%
Net income-$4.9M-102%
EPS (diluted)-$0.05-103%

Balance sheet

See full
Cash & equivalents$571.1M+11.9%
Total debt$198.2M-7.6%
Total equity$1.5B+8.8%
Total assets$3.2B-13.4%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$555.0K-98.3%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.77B+10.9%
Enterprise value$1.4B+7.5%
P/S0.9×

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin-6.9%
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-9.3%+2,662pp
Debt / equity0.1×0.0×
Current ratio4.4×+1.5×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept srpt:OtherSegmentItems.

The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:01 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335003
Line itemFor the Three Months Ended June 30, 2026For the Three Months Ended June 30, 2025For the Six Months Ended June 30, 2026For the Six Months Ended June 30, 2025
Research and development- other (excluding non-cash items) (1)19,84731,84338,51860,314
Selling, general and administrative- other (excluding non-cash items) (2)42,46256,32282,655107,464
Roche collaboration reimbursement(7,169)(25,689)(15,358)(54,170)
Other segment items (3)(709)(1,314)(2,515)(3,223)
Loss (gain) on strategic investments448(36,721)2,16054,007
Interest expense21,5085,22843,2219,731
Interest income(6,207)(5,254)(12,567)(15,444)
Income tax expense (benefit)3,141(43,254)15,35620,736

Item 1. Financial Statements

FAQ

What is Sarepta Therapeutics, Inc.'s business segments — other segment items?
Sarepta Therapeutics, Inc. (SRPT) reported business segments — other segment items of -$709K in Q2 2026.
How has Sarepta Therapeutics, Inc.'s business segments — other segment items changed year-over-year?
Sarepta Therapeutics, Inc.'s business segments — other segment items increased by 46.0% year-over-year, from -$1.31M to -$709K.
What is the long-term trend for Sarepta Therapeutics, Inc.'s business segments — other segment items?
Over 2 years (2022 to 2024), Sarepta Therapeutics, Inc.'s business segments — other segment items has grown at a 73.7% compound annual growth rate (CAGR), from -$11.01M to -$33.23M.
What does business segments — other segment items mean?
Captures non-recurring or miscellaneous financial items specific to the segment that do not fit into standard operating expense categories. It is used to reconcile segment-level performance and identify unique operational adjustments.

Ask your AI about Sarepta Therapeutics, Inc.'s business segments — other segment items.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude